Parkinson's Disease - Evidence of neuroprotection essential to progress treatment dynamics

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2007-12-19

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Parkinson's disease (PD) is a progressive, degenerative condition of the central nervous system that affects the way the brain coordinates body movements, including walking, talking and writing. PD affects less than 1% of the population in the seven major markets (7MM); with patients typically being diagnosed in their early sixties and living for over 18 years after the onset of first symptoms.


Scope

  • Overview of epidemiology, presentation, and diagnostic assessment in PD
  • Breakdown of first-line treatment regimens for early-, mid-, and advanced-stage disease, with analysis of second-line add-on and switching dynamics
  • Influences on neurologists' treatment decisions and their perception of current brands
  • Evaluation of treatment outcomes and surgical procedures for PD


    • Report Highlights
    Neurologists indicated that the DAs Mirapex (pramipexole) and Requip (ropinirole) are generally the initial treatment of choice for younger presenting patients. While levodopa is reserved for patients over 65 years of age, neurologists may prescribe the MAOIs selegiline and rasagiline (Azilect) in young patients with only mild symptoms at onset.

    Neurologists indicated that only 36% of advanced-stage PD patients are adequately controlled by pharmacological therapy. Considering the even distribution of patient severities (30% early-stage, 39% mid-stage and 31% advanced-stage), the advanced-stage patient group is particularly poorly served by current therapies.

    Neurologists estimated that approximately 9% of all PD patients will eventually require surgery. Deep Brain Stimulation is by far the most common surgical procedure used in the 7MM and neurologists indicated that over 70% of patients receiving it experience both a reduction in PD symptoms and a reduction in the dose of pharmacological medication.


    Reasons to Purchase

  • Target prescribers more effectively, through an understanding of prescribing behavior and its influences
  • Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products
  • Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies

    • Table of Contents

    Other users found this report page using the following search terms: neuroprotection neurodegenerative parkinsons parkinsons disease treatment parkinson neuroprotection timeline azilect mirapex stage sales

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.